Docetaxel

證據等級: L5

預測適應症: 10 個

Docetaxel: From Solid Tumor Chemotherapy to Female Breast Carcinoma

One-Sentence Summary

Docetaxel (Taxotere) is a semisynthetic taxane — one of the most widely used cytotoxic chemotherapy agents globally for solid tumors, including breast cancer, non-small cell lung cancer, and prostate cancer — though it currently holds no Medsafe authorization in New Zealand. The TxGNN model predicts it may be effective for Female Breast Carcinoma in the New Zealand setting, with 50 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Solid tumor chemotherapy (taxane class; no New Zealand registration)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.90%
Evidence Level	L1
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Docetaxel is a semisynthetic taxoid derived from the European yew tree (Taxus baccata). As a microtubule-stabilizing agent, it promotes the assembly of tubulin into stable microtubule bundles while inhibiting their depolymerization. This hyperstabilization blocks the metaphase-to-anaphase transition during mitosis, arresting the cell cycle and inducing apoptosis preferentially in rapidly proliferating cancer cells.

Female breast carcinoma is characterized by high proliferative activity, making it particularly susceptible to taxane-class agents. Docetaxel has been a cornerstone of breast cancer treatment globally for over two decades. Multiple Phase 3 randomized controlled trials have established significant overall survival (OS) and disease-free survival (DFS) benefits across all major treatment settings: neoadjuvant (AC→T, TCHP), adjuvant (TAC, TC, dose-dense regimens), and metastatic (single-agent or combination with capecitabine, trastuzumab, pertuzumab). The mechanistic match between taxane action and breast carcinoma biology is exceptionally well-characterized and broadly replicated.

Although docetaxel holds no current Medsafe authorization in New Zealand, its extensive global regulatory approval record — FDA (1996), EMA, and multiple Asian health authorities — and the weight of its clinical evidence base make it a strong candidate for a Medsafe abridged or bibliographic regulatory pathway. The TxGNN model's high prediction score (99.90%) is consistent with this established evidence, reflecting the model's ability to correctly identify drugs with robust cross-validated clinical signals.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002707	Phase 3	Completed	2,411	Large RCT comparing preoperative AC vs. AC+docetaxel (pre- or post-operative) in Stage II/III breast cancer; established the neoadjuvant docetaxel backbone
NCT00089479	Phase 3	Completed	2,611	AC→docetaxel vs. AC→docetaxel+capecitabine in high-risk breast cancer; confirmed AC→T as standard adjuvant backbone
NCT01275677	Phase 3	Completed	3,270	TC or AC→paclitaxel ± trastuzumab in HER2-low invasive breast cancer; large adjuvant RCT confirming taxane regimen efficacy across HER2 subtypes
NCT00193011	Phase 3	Completed	150	Weekly docetaxel vs. CMF as adjuvant therapy in breast cancer patients ≥65 years or unsuitable for anthracyclines; supports docetaxel use in older/frail patients
NCT00002544	Phase 3	Completed	300	Mitoxantrone vs. FEC (with/without docetaxel) as first-line chemotherapy for metastatic breast cancer with poor prognosis; established first-line efficacy benchmarks
NCT01354522	Phase 3	Completed	204	TAC vs. TCX (docetaxel/cyclophosphamide/capecitabine) as adjuvant therapy in HER2-negative breast cancer; evaluated capecitabine addition to taxane backbone
NCT00431080	Phase 3	Completed	478	Dose-dense G-CSF-supported FEC→docetaxel vs. paclitaxel as adjuvant chemotherapy in node-positive breast cancer; supports taxane sequencing in high-risk disease
NCT02003209	Phase 3	Completed	315	TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) ± estrogen deprivation in HR+/HER2+ locally advanced breast cancer; key pCR data with dual HER2 blockade
NCT04066335	Observational	Unknown	1,498	Large observational safety study of Nanoxel M (docetaxel nanoparticle formulation) in cancer patients including breast cancer; real-world tolerability data at scale
NCT00003565	Phase 2	Completed	109	Population pharmacokinetics of docetaxel in Caucasian and African-American solid tumor patients; supports individualized dosing and ethnic PK considerations

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28398846	2017	Phase 3 RCT	J Clin Oncol	ABC Trials (USOR 06-090, NSABP B-46-I, NSABP B-49): TC×6 vs. TaxAC in early breast cancer; demonstrated TaxAC superiority in high-risk disease, defining current adjuvant standard
11481357	2001	Phase 2 RCT	J Clin Oncol	Dose-dense doxorubicin+docetaxel ± tamoxifen as preoperative therapy in operable breast cancer; high pathological response rates with dose-dense taxane-anthracycline approach
12599222	2003	Phase 2	Cancer	Capecitabine + docetaxel + epirubicin (TEX) as first-line in locally advanced/metastatic breast carcinoma; promising activity and manageable toxicity in triple combination
27997437	2017	Cohort	Anti-cancer Drugs	Retrospective study on adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema; identified fluid retention syndrome as a contributing risk factor
19856651	2009	Phase 1/2	Tumori	Dose-finding study of weekly docetaxel + gemcitabine in anthracycline-refractory metastatic breast cancer; established feasible combination schedule for second-line use
9364543	1997	Phase 2	Oncology	Docetaxel + vinorelbine combination in metastatic breast cancer and NSCLC; response rates 23–36% confirming docetaxel's broad single-agent and combination activity
26874836	2017	Retrospective	Breast Cancer (Tokyo)	Docetaxel + cyclophosphamide + trastuzumab (HER-TC) as neoadjuvant chemotherapy in HER2+ breast cancer; evaluated pCR rates by hormone receptor subtype
15585076	2004	Phase 2	Clin Breast Cancer	Docetaxel + cisplatin as primary chemotherapy for locally advanced breast cancer (≥5 cm); pCR evaluation with platinum-taxane neoadjuvant combination
15161988	2004	Review	The Oncologist	Comprehensive 10-year clinical experience review of paclitaxel and docetaxel in breast cancer across metastatic, adjuvant, and neoadjuvant settings
7595719	1995	Review	J Clin Oncol	Foundational review of docetaxel's preclinical and clinical profile; established the scientific rationale for taxoid use in solid tumor oncology

New Zealand Market Information

Docetaxel currently holds no Medsafe authorizations in New Zealand. There are no registered products to list.

Note: Docetaxel is approved in numerous other jurisdictions — including the United States (FDA, 1996), European Union (EMA), Japan (PMDA), and Taiwan — for breast cancer, NSCLC, prostate cancer, gastric cancer, and head and neck cancer. A Medsafe application referencing these established international approvals via an abridged or bibliographic data pathway would be the recommended regulatory route.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Taxane class (microtubule-stabilizing agent; semisynthetic taxoid)
Myelosuppression Risk	High — Neutropenia is the dose-limiting toxicity; febrile neutropenia occurs in 25–40% of patients without G-CSF prophylaxis. Thrombocytopenia and anaemia also reported. Primary G-CSF prophylaxis is recommended with most standard regimens
Emetogenicity Classification	Low to moderate (lower emetogenic potential than anthracyclines; dexamethasone premedication is standard to reduce fluid retention and hypersensitivity reactions)
Monitoring Items	CBC with differential (before each cycle); liver function tests (ALT, AST, total bilirubin, alkaline phosphatase — dose adjustment required if elevated); renal function; weight and fluid status (edema/fluid retention); peripheral neuropathy assessment; cardiac monitoring when combined with anthracyclines
Handling Protection	Must follow cytotoxic drug handling regulations — closed-system drug transfer devices (CSTDs) recommended; appropriate PPE required (double chemotherapy-rated gloves, gown, eye protection) during preparation and administration

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Docetaxel has one of the strongest clinical evidence bases in oncology for female breast carcinoma, with multiple completed Phase 3 RCTs demonstrating OS and DFS benefits across neoadjuvant, adjuvant, and metastatic settings (L1 evidence level). The primary barrier to clinical use in New Zealand is the absence of a Medsafe authorization, not any gap in clinical efficacy data.

To proceed, the following is needed:

Submission of a Medsafe authorization application referencing existing FDA/EMA approvals (abridged or bibliographic regulatory pathway)
Full New Zealand-compliant prescribing information including contraindications, black-box warnings (neutropenia, hypersensitivity reactions, fluid retention), and dosing guidance
Pharmacovigilance plan for post-market safety monitoring in the New Zealand setting
G-CSF prophylaxis protocol assessment and local formulary integration with New Zealand oncology pharmacy services
Breast cancer multidisciplinary team (MDT) endorsement and integration into local treatment pathways (neoadjuvant, adjuvant, and metastatic protocols)
HER2 testing infrastructure confirmation to ensure appropriate patient selection for trastuzumab/pertuzumab-containing docetaxel regimens
Assessment of any ethnicity-specific pharmacokinetic considerations relevant to the New Zealand patient population (Māori, Pasifika)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.